The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Eli Lilly’s retatrutide posts Phase 3 gains across obesity, type 2 diabetes, knee osteoarthritis pain and sleep apnea
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 7, 6:28 AM EDT

Eli Lilly’s retatrutide posts Phase 3 gains across obesity, type 2 diabetes, knee osteoarthritis pain and sleep apnea

In two pivotal Phase 3 trials, Lilly said its investigational triple-agonist retatrutide drove large weight loss and improved A1C, knee osteoarthritis pain, and moderate-to-severe obstructive sleep apnea severity.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly and Company (NYSE: LLY) said its investigational obesity drug retatrutide produced substantial improvements across multiple obesity-related conditions in two pivotal Phase 3 trials. In results announced June 6, Lilly reported that retatrutide reduced body weight while also lowering measures of knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea severity in one study, and improving blood sugar control and weight in a second study in adults with type 2 diabetes.

Retatrutide is a once-weekly, first-in-class “triple hormone receptor agonist” that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly said the company is still studying the molecule and that it is investigational and legally available only to participants in its clinical trials.

For the TRIUMPH-1 program, Lilly described a Phase 3, 80-week, randomized, double-blind, placebo-controlled “master trial” that included obesity and two nested basket trials focused on knee osteoarthritis pain and obstructive sleep apnea. The study enrolled 2,339 participants randomized to retatrutide 4 mg, 9 mg, 12 mg, or placebo. Lilly said retatrutide met primary endpoints for each basket at 80 weeks, with the company describing average weight loss of 64.4 pounds (25.9%) for the 9 mg dose and 70.3 pounds (28.3%) for the 12 mg dose.

Lilly said the same TRIUMPH-1 data showed “meaningful improvements” beyond weight. In participants with knee osteoarthritis, retatrutide reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores by up to 4.3 points (73.1%) from a baseline of 6.0. In participants with moderate-to-severe obstructive sleep apnea, Lilly said retatrutide reduced the apnea-hypopnea index (AHI) by up to 36.1 events per hour (60.6%), from a baseline of 58.6. Lilly also reported a pre-specified extension for participants with baseline body mass index (BMI) of at least 35, with those continuing on the 12 mg dose through 104 weeks losing an average of 85.0 pounds (30.3%).

In a separate Phase 3 trial, TRANSCEND-T2D-1, Lilly said retatrutide improved A1C and supported weight loss in adults with type 2 diabetes. The 40-week, randomized, double-blind, placebo-controlled study enrolled 537 participants randomized to retatrutide 4 mg, 9 mg, 12 mg, or placebo. Lilly said retatrutide met its primary endpoint and key secondary endpoints at 40 weeks, with average A1C reductions of up to 2.0% from a baseline of 7.9%. Lilly reported that up to 90% of participants taking retatrutide achieved A1C below 7.0%, and up to 85% reached A1C at or below 6.5%, with up to 46% achieving A1C below 5.7%.

Lilly said TRANSCEND-T2D-1 participants also experienced weight loss, including an average loss of up to 36.6 pounds (16.8%) for the 12 mg dose at 40 weeks, with Lilly stating weight loss had not yet plateaued at that time. The company also reported reductions in several cardiovascular risk factors in both trials, including decreases in triglycerides, non-HDL cholesterol, systolic blood pressure, and waist circumference, though it did not provide longer-term cardiovascular outcomes in this announcement.

Lilly said the adverse events seen in TRIUMPH-1 and TRANSCEND-T2D-1 were generally consistent with other incretin-based therapies. In TRIUMPH-1, common events included nausea, diarrhea, constipation, vomiting, and upper respiratory tract infections, while Lilly reported incidences of dysesthesia and urinary tract infections as well. The company said discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% across retatrutide doses in TRIUMPH-1, and 2.2%, 4.5%, and 5.1% across doses in TRANSCEND-T2D-1, versus 4.9% and 0.0% with placebo, respectively.

Why It Matters

  • The results broaden retatrutide’s potential positioning from weight loss toward treating multiple downstream obesity complications in one program.
  • If additional Phase 3 readouts and regulatory reviews confirm these multi-condition benefits, Lilly could differentiate retatrutide versus therapies that focus primarily on weight or a single metabolic endpoint.
  • The company provided improvements in A1C and several cardiovascular risk factors but did not disclose longer-term cardiovascular outcomes in this announcement, leaving uncertainty about ultimate event reduction.
  • Adverse events and discontinuation rates remain important, especially at higher doses, and Lilly’s disclosure underscores the need to balance efficacy with tolerability for any future use.

Sources

Key Facts

  • Lilly reported Phase 3 results for retatrutide in TRIUMPH-1 (80 weeks) and TRANSCEND-T2D-1 (40 weeks).
  • In TRIUMPH-1, retatrutide 9 mg and 12 mg produced average weight losses of 64.4 pounds (25.9%) and 70.3 pounds (28.3%), respectively.
  • TRIUMPH-1 also showed retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and reduced obstructive sleep apnea severity (AHI) by up to 36.1 events per hour (60.6%).
  • In TRANSCEND-T2D-1, retatrutide achieved A1C reductions of up to 2.0% from a baseline of 7.9%, with up to 90% reaching A1C below 7.0%.
  • Lilly said weight loss in TRANSCEND-T2D-1 was up to 36.6 pounds (16.8%) at 40 weeks and had not yet plateaued by the study endpoint.
  • Lilly reported common side effects consistent with incretin therapies, including nausea, diarrhea, constipation, vomiting, and upper respiratory tract infections, with discontinuation rates due to adverse events varying by dose.

Healthcare Related